EAU 2013 - Programme Book - YouMed

Sponsored Sessions
Saturday, 16 March
408 Programme Book
Sponsored Session
18.00 - 19.30 Premature ejaculation treatment: New perspectives for the couple
Yellow Hall 1-2-3 - Level N1
Symposium
Chair: I. Moncada, Madrid (ES)
Opening and welcome
I. Moncada, Madrid (ES)
Premature ejaculation: Looking beyond a male sexual dysfunction
A. Graziottin, Milan (IT)
Premature ejaculation diagnosis and treatment in daily practice
I. Eardley, Leeds (GB)
Premature ejaculation on demand treatment with dapoxetine: From clinical evidence to real practice
D.G. Hatzichristou, Thessaloniki (GR)
Q&A and closing remarks
I. Moncada, Madrid (ES)
Aims and objectives
Premature Ejaculation (PE) is the most prevalent male sexual dysfunction that affects multiple dimensions
of the patient’s life, ranging from personal to relational domains, with a major effect on couple sexual
relationship as demonstrated by observational studies. Despite of that, significant barriers to obtaining
assistance from physicians exist and PE remains often under-diagnosed and consequently under-treated so,
further efforts to promptly identify and approach PE are required.
Dapoxetine is a fast-acting SSRI, specifically developed for the on demand treatment of PE. Its clinical efficacy
and safety have been demonstrated in 5 phase III clinical trials that involved 6,081 men diagnosed with PE,
in over 25 countries, showing an improvement in IELT and subjective measures of perceived amelioration in
terms of control over ejaculation, satisfaction with sexual intercourse, personal distress and interpersonal
difficulty. Recent trials provided interesting findings on the effect of Dapoxetine in daily practice, strengthen
its positive safety profile and provide a preliminary picture of the trend of utilization in real life.
Sponsored by MENARINI